Bezisterim (NE3107)
Alzheimer's Disease
Key Facts
About BioVie
BioVie is a clinical-stage biotechnology company with a mission to unlock the science of longevity by targeting the inflammatory and metabolic roots of age-related diseases. Its core strategy is built around bezisterim (NE3107), a novel, orally-administered small molecule designed to selectively modulate neuroinflammation and improve insulin sensitivity in the brain. The company has advanced bezisterim into Phase 2/3 trials for Alzheimer's disease and Phase 2 studies for Parkinson's disease and Long COVID, while concurrently exploring its epigenetic impact on aging. A second clinical program, BIV201, is being developed for the treatment of refractory ascites due to liver cirrhosis.
View full company profileAbout BioVie
BioVie is a clinical-stage biotechnology company with a mission to unlock the science of longevity by targeting the inflammatory and metabolic roots of age-related diseases. Its core strategy is built around bezisterim (NE3107), a novel, orally-administered small molecule designed to selectively modulate neuroinflammation and improve insulin sensitivity in the brain. The company has advanced bezisterim into Phase 2/3 trials for Alzheimer's disease and Phase 2 studies for Parkinson's disease and Long COVID, while concurrently exploring its epigenetic impact on aging. A second clinical program, BIV201, is being developed for the treatment of refractory ascites due to liver cirrhosis.
View full company profileAbout BioVie
BioVie is a clinical-stage biotechnology company with a mission to unlock the science of longevity by targeting the inflammatory and metabolic roots of age-related diseases. Its core strategy is built around bezisterim (NE3107), a novel, orally-administered small molecule designed to selectively modulate neuroinflammation and improve insulin sensitivity in the brain. The company has advanced bezisterim into Phase 2/3 trials for Alzheimer's disease and Phase 2 studies for Parkinson's disease and Long COVID, while concurrently exploring its epigenetic impact on aging. A second clinical program, BIV201, is being developed for the treatment of refractory ascites due to liver cirrhosis.
View full company profileTherapeutic Areas
Other Alzheimer's Disease Drugs
| Drug | Company | Phase |
|---|---|---|
| NUZ-001 | Neurizon Therapeutics | Preclinical |
| ALZN002 | Alzamend Neuro | Preclinical |
| P021 | Phanes Biotech | Preclinical |
| PB43D | Phanes Biotech | Preclinical |
| UB-311 | Vaxxinity | Phase 2 |
| Lecanemab | BioArctic | Launched |
| BAN2401 | BioArctic | Preclinical |
| Undisclosed Programs | johnson-and-johnson-innovative-medicine | Pipeline |
| MK-6240 (florquinitau) | Lantheus Medical Imaging | Regulatory Filing |
| NAV-4694 (flutafuranol) | Lantheus Medical Imaging | Phase 3 |
| LNTH-2620/PI-2620 | Lantheus Medical Imaging | Phase 3 |
| itMSCs | Stemedica Cell Technologies | Clinical Development |